Enliven Therapeutics Inc. (Nasdaq: ELVN) reported this week that as of the end of 2025, the clinical-stage precision oncology company has $462.6 million in cash and equivalents, enough runway to fund ...

In Part 4, Carolyn Krause learns more about the processes behind BWXT and LIS Technologies, which will be part of the nuclear ...

There are now signs also in the USA that the importance of a positive human-animal relationship in research laboratories is appreciated more seriously, and that in addition to knowledge and skills, ...